It has been explored for the treatment of ATLL and HAM/TSP in clinical trials and is approved for the treatment of patients with relapsed or refractory CCR4+ ATLL in Japan [19,20]. Here, CCR4 is linked to adult T-cell leukemia/lymphoma.